Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

(June 26, 2025) by Annalee Armstrong.

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic mitochondria.

Minovia Therapeutics, an Israeli biotech hoping to get to the root causes of disease and aging, is planting itself onto the Nasdaq through a special purpose acquisition company transaction valued at $180 million.

The company will combine with Launch One Acquisition Corp. to become Mito US One, according to a Wednesday press release. The result will be a publicly traded biotech focused on Minovia’s mitochondrial augmentation technology, a platform that finds therapies for diseases driven by mitochondrial dysfunction.